[ad_1]
This article is over a month old and may contain outdated advice from authorities regarding coronary heart disease.
Stay up to date on the NRK overview or on the FHI website.
The EMA is considering four vaccines and initial approval may come around the New Year.
– An approval there means that it is approved in Noge. We hope to be able to offer the first doses early next year. Norway will receive up to 2.5 million doses in the first quarter. This means that 1,250,000 people can receive two doses each. It constitutes more than 70 percent of all the people in the risk group and of the health personnel who work in contact with patients.
– Then we will be in a completely different situation until today than today, says Høie.
Palm Sunday falls on March 28 of next year.
– More normal towards summer
The news came yesterday that vaccine maker Pfizer only manages to deliver half the vaccines they expected before the New Year. The plan was to administer 100 million doses.
However, the company believes that delivery issues will have no consequences for the plan to deliver 1 billion vaccines in 2021.
– We expect good access during the first half of the year. Then we can have a more normal everyday life again in the summer, but it depends on what is approved, says Høie.
Høie hopes that many will take the vaccine, but emphasizes that the vaccine will be free and that getting vaccinated will be voluntary.
Take the advice of experts
The expert committee of the Norwegian Institute of Public Health concluded in November that the elderly and infirm should receive the coronary vaccine first.
The committee believes that the consideration that outweighs anything else when launching the vaccine is preventing serious illness and death.
The Government agrees with the assessment.
– There will not be enough vaccines for everyone at once. The most important thing is to reduce the risk of death and serious illness. Therefore, the offer will go first to risk groups and then to health personnel. We have to prioritize, but that’s only at the beginning, says Høie.
The priority can be changed if the infection increases.
Contact risk groups
1.3 million Norwegians are over 65 years of age or suffer from diseases that increase the risk of serious diseases.
– We do not regain daily life as soon as vaccination begins. Infection control measures still need to be taken while it is underway. We have to take one thing at a time, says Høie.
Those who are prioritized in the first round will be contacted. You do not need to register.
Director of Infection Control Geir Bukholm states that nursing home residents, people over 65, and people with one or more diseases that increase the risk of a serious course of disease are at the top of the list. list.
– The entire risk group cannot be covered at the same time. To solve it, you have to have even more detailed priorities. It will go back to when we have an approved vaccine and know how many doses we got in the first place, says Bukholm.
Municipalities have the responsibility to carry out vaccination.
AstraZeneca, University of Oxford
The corona vaccine developed at the University of Oxford prevents the symptoms of COVID-19 in 70 percent of cases.
The AZD1222 vaccine is based on the monkey ChAdOx1 virus. This virus is modified so that it cannot make copies of itself, so it does not lead to disease. The researchers also changed the virus to carry additional information. The additional information causes your body to produce the so-called “spike protein” of the coronavirus.
What happens is the following: You get the vaccine in your body. The vaccine virus enters your cells. Inside cells, the production system discovers the additional information. Many copies of the “spike protein” are made. These copies are secreted by cells. Your immune system detects these proteins. An immune response is triggered. Antibodies against the coronavirus are produced and the immune system remembers that it is something to react to.
You have been vaccinated.
Biontech, Fosun Pharma and Pfizer
The German pharmaceutical company BioNTech reports that its coronary vaccine has been shown to be 95 percent effective. The UK will start vaccinating in December.
The BNT162b2 vaccine relies on your body’s system for building things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells use all the time for this purpose. These are called mRNAs or “messenger ribonucleic acids.”
What happens is the following:
The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines build copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something foreign to react to.
You have been vaccinated.
Johnson and Johnson
The vaccine is in phase 3 of development.
Ad26 vaccine. COV2.S is based on the ad26 virus. It is a cold virus that circulates among humans. This is the virus that has been modified by researchers so that it cannot cause disease in humans. It also carries an extra gene, a bit of extra information. The extra information causes your body to produce the so-called “spike protein” of the coronavirus.
What happens is the following:
You get the vaccine in your body. The vaccine virus enters your cells. Inside cells, the production system discovers the additional information. Many copies of the “spike protein” are made. These copies are secreted by cells. Your immune system detects these proteins. An immune response is triggered. Antibodies against the coronavirus are produced and the immune system remembers that it is something to react to.
You have been vaccinated.
Novavax with partners
Novavax expects results in early 2021.
The NVX-CoV2373 vaccine is based on what are called nanoparticles. These are microscopic structures. The Novavax vaccine has nanoparticles that are primarily an extract from the Quillaja saponaria plant. This extract is used in much of the world as a food additive, but it also has medicinal properties. In addition, the vaccine particles are made up of cholesterol and fatty acids. The particles also carry the “spike protein” of the coronavirus. These nails are produced in genetically modified yeast cells and are added to the particles in the production process.
What happens is the following:
The vaccine works in two ways. Nanoparticles make your immune system respond better and spike proteins make the immune system react as if a real coronavirus has entered the body.
You have been vaccinated.
Modern
US Secretary of Health Alax Azar says that the coronary vaccine at Pfizer and Moderna can be approved and distributed in a few weeks.
The mRNA-1273 vaccine relies on your body’s system to build things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells use all the time for this purpose. These are called mRNAs or “messenger ribonucleic acids.”
What happens is the following:
The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines build copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something foreign to react to.
You have been vaccinated.
In this phase, the vaccine is given to a small group of young, healthy people to see if the immune system responds. Researchers are also looking into whether it causes powerful and perhaps dangerous side effects. Also, based on the results, it is estimated how much vaccine should be administered.
In this phase, the vaccine is given to a larger group that is made up more broadly. The goal is to find variations in the immune system response and more data on side effects and the most reasonable amount of vaccine.
In this phase, it is investigated if the vaccine provides protection against the disease and if it causes more rare side effects. Several thousand people receive the vaccine and several thousand people receive a sham vaccine. Nobody knows who gets what. This is to ensure good scientific data.
The vaccine is ready for distribution.
The vaccine is approved for use in the EU and Norway.
